Harrow draws $30M under Oaktree loan for Novartis Triescence milestone; amends credit terms

HARROW, INC.

Drew $30M on Oct 25, 2024, under Oaktree Loan to partially fund $37M milestone to Novartis for Triescence commercial availability.
Total drawn under Oaktree Loan now $107.5M; no additional borrowing capacity remains.
Oaktree waived make-whole costs on the $30M draw if repaid before March 31, 2025.
Second Amendment excludes the $30M draw from Total Leverage Ratio calculation.
Milestone payment for Triescence was made on October 15, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.